CONCORD

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

Retrieved on: 
Tuesday, November 14, 2023
DARPin, RDT, Immune system, Senior, Tetra, Service provider, ASH, CD70, CD40, Patient, Tumor microenvironment, Immunotherapy, Neoplasm, Therapy, FAP, Exposition, Novartis, CD33, Cancer, Trial of the century, SITC, Toxic epidermal necrolysis, Partnership, AML, Society, Molecular Partners, Myelodysplastic syndrome, CD123, Cell, CD3, Medical imaging, Vaccine, Research, CONCORD

The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions.

Key Points: 
  • The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions.
  • This conditional activation is intended to focus immune attack more specifically against tumor cells and minimize damage to healthy cells, a major challenge for current oncology drugs and development efforts.
  • The SWITCH-DARPin platform, a versatile novel DARPin design for conditionally triggering an immune cell attack only in the presence of defined tumor antigens.
  • The portfolio of RDT candidates represent a unique delivery system for radioactive payloads to solid tumors and has significantly expanded the company’s work in oncology therapeutics.

National Construction Firm Shift Leadership: Succession Continues Strategic Vision

Retrieved on: 
Tuesday, December 12, 2023
Civic, Quartz, Construction, Senior, Executive Committee, Imagination, Facility Solutions Group, County, Foster, Engineering, procurement, and construction, University, Public–private partnership, Employee benefits, Retirement, Growth, Management, Science, Callis, Swinerton, CONCORD, Engineering

CONCORD, Calif., Dec. 12, 2023 /PRNewswire-PRWeb/ -- Swinerton Incorporated (Swinerton) announces Chief Executive Officer (CEO) Eric Foster's retirement on January 11, 2024. The Swinerton Incorporated Board of Directors has elected current Swinerton President David Callis as the next CEO of both Swinerton and its subsidiaries, including Swinerton Builders. Foster and Callis have worked to ensure a seamless transition since the shift was announced internally to employee-owners in June 2023.

Key Points: 
  • CONCORD, Calif., Dec. 12, 2023 /PRNewswire-PRWeb/ -- Swinerton Incorporated (Swinerton) announces Chief Executive Officer (CEO) Eric Foster's retirement on January 11, 2024.
  • Foster and Callis have worked to ensure a seamless transition since the shift was announced internally to employee-owners in June 2023.
  • He is committed to our forward vision and growing our employee-ownership model," expresses Foster.
  • His visionary leadership will undoubtedly propel Swinerton into the future, building upon its solid foundation and expanding its reputation as a trusted construction partner.

The North Star Capital Fund LLC Reports Investor Third Quarter Return of 10.15% APR!

Retrieved on: 
Monday, December 4, 2023
APR, Pressure, Fund, Risk, Feds, Investment, Capital, Housing, Growth, San Francisco Bay Area, Fed, Real estate, CONCORD, Greater Los Angeles

CONCORD, Calif., Dec. 4, 2023 /PRNewswire/ -- After the end of the third quarter of 2023, The North Star Capital Fund LLC ("Fund') reported a remarkable 10.15% APR net return for its Fund Members. For Fund Members who have reinvested or "rolled over" all their distributions, their return since inception is an extraordinary 13.40% APR. Since inception, the APR net return for Fund Members that take quarterly distributions is 11.29%. "The performance of the Fund since inception has been exceptional," states John W. Simonse, President of LHJS Investments LLC ("LHJS") and a Managing Member of the Fund. "The Fund continues to outperform similar funds by almost 50%!" Mr. Simonse goes on to say that "For investors who prefer a secure investment, one not subject to the volatility of the market, The North Star Capital Fund is an excellent choice. Every quarter since the Fund's inception, over three years ago, the Fund has returned at least 10 % net APR to its investors."

Key Points: 
  • The North Star Capital Fund LLC is currently open for new capital investment!
  • CONCORD, Calif., Dec. 4, 2023 /PRNewswire/ -- After the end of the third quarter of 2023, The North Star Capital Fund LLC ("Fund') reported a remarkable 10.15% APR net return for its Fund Members.
  • For Fund Members who have reinvested or "rolled over" all their distributions, their return since inception is an extraordinary 13.40% APR.
  • "The performance of the Fund since inception has been exceptional," states John W. Simonse, President of LHJS Investments LLC ("LHJS") and a Managing Member of the Fund.

Graham Smith Named Vice President of OEM Partnerships

Retrieved on: 
Tuesday, November 21, 2023
Speedway Motorsports, Ford, Business development, Furman University, NASCAR, History, OEM, Communication studies, U.S, Operation, Business operations, Original equipment manufacturer, US Legend Cars, Smith, Management, Automotive industry, CONCORD

CONCORD, N.C., Nov. 21, 2023 /PRNewswire/ -- Speedway Motorsports (SM) officials announced that Graham Smith, formerly Vice President of Business Operations for U.S. Legend Cars International, has been named Vice President of OEM Partnerships. In his new role on behalf of Speedway Motorsports, Smith will be devoted to further strengthening company relationships among original equipment manufacturers (OEMs); building unique corporate events with OEMs around driving experiences and cultivating new partnerships with OEMs to utilize Speedway Motorsports properties.

Key Points: 
  • CONCORD, N.C., Nov. 21, 2023 /PRNewswire/ -- Speedway Motorsports (SM) officials announced that Graham Smith, formerly Vice President of Business Operations for U.S. Legend Cars International , has been named Vice President of OEM Partnerships.
  • Under the direction of SM Executive Vice President and Chief Sales Officer Kevin Camper, Smith will work with corporate sales and track operations staff at Speedway Motorsports' 11 premier facilities across the United States.
  • Smith was then promoted to vice president of business operations in 2022.
  • I'm thrilled to now have the opportunity to invest my time and energy into our OEM business through even more meaningful relationships, partnerships and creative uses of our facilities."

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Patient, Biomarker, FAP, Therapy, Molecular Partners, Poster, SITC, Immunotherapy, Interferon gamma, Annual general meeting, Serum, Tumor microenvironment, CXCL10, Safety, Society, DARPin, CMO, TME, CD40, Medical imaging, Pharmaceutical industry, Vaccine, CONCORD

MP0317 is a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment (TME) by anchoring to fibroblast activation protein (FAP).

Key Points: 
  • MP0317 is a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment (TME) by anchoring to fibroblast activation protein (FAP).
  • “The encouraging results presented at SITC provide clinical evidence of MP0317-induced, tumor-targeted CD40 activation.
  • The positive results of this fully enrolled Phase 1 study in patients with refractory/relapsed tumors support continued clinical evaluation of MP0317 and potential investigation in combination studies.
  • Patients received MP0317 at doses of 0.03–10 mg/kg in every-3-weeks (Q3W) or weekly (Q1W) schedules (data cut-off 10 October 2023).

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

Retrieved on: 
Thursday, November 2, 2023
CD3, CD70, Therapy, Antigen, CD123, Myelodysplastic syndrome, 65th Aggressor Squadron, Tetra, Society, Pharmacokinetics, ASH, CD33, Bone marrow, Molecular Partners, Safety, DARPin, Cellular, Transplant, AML, Pharmaceutical industry, Vaccine, Medical device, Patient, CONCORD

MP0533 is in development for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (AML/MDS).

Key Points: 
  • MP0533 is in development for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (AML/MDS).
  • As of data cut-off (20 July 2023) of the abstract published today, five patients across three dosing regimens had been treated.
  • The Company anticipates to present data including from the fourth dose cohort at the ASH Annual Meeting and Exposition in December this year.
  • “The data from the ASH abstract represent the beginning of an exciting and encouraging clinical journey for the MP0533 program.

Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit

Retrieved on: 
Wednesday, November 1, 2023
News, Molecular Partners, New Çeltek events, TD, CMO, DARPin, Webcast, Therapy, Fine chemical, Online shopping, CONCORD

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will participate in a fireside chat at the TD Cowen 7th Annual Fall Oncology Innovation Summit on Friday, November 3, 2023 at 9:00 a.m.

Key Points: 
  • ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will participate in a fireside chat at the TD Cowen 7th Annual Fall Oncology Innovation Summit on Friday, November 3, 2023 at 9:00 a.m.
  • Presenting on behalf of Molecular Partners will be Patrick Amstutz, Chief Executive Officer, and Dr. Philippe Legenne, acting CMO.
  • A live webcast of the event will be available on the "News and Events" page in the "Events" section of the Company's website .
  • A replay of the webcast will be archived on the Company's website for 90 days following the presentation date.

2023 Sees Largest and Most Diverse Incoming Class of UNH Franklin Pierce Hybrid JD Program

Retrieved on: 
Monday, October 30, 2023
STEM, Female, Dean (education), Education, Pepsi, ABA, JD, Student, Microsoft, Enrollment, Motivation, CONCORD, Intellectual property, Administration, Growth, Careers New Zealand, University, Hybrid, WeWork, IP, Freedom of information laws by country, Samsung, Nursing, Bayer, Law

CONCORD, N.H., Oct. 30, 2023 /PRNewswire/ -- The University of New Hampshire Franklin Pierce School of Law has welcomed its largest incoming class in their Hybrid JD in Intellectual Property, Technology & Information Law since launching the program in 2019.

Key Points: 
  • CONCORD, N.H., Oct. 30, 2023 /PRNewswire/ -- The University of New Hampshire Franklin Pierce School of Law has welcomed its largest incoming class in their Hybrid JD in Intellectual Property, Technology & Information Law since launching the program in 2019.
  • "Our Hybrid JD students bring incredible experiences—and their whole selves—to the virtual classroom and in-person sessions," said Megan Carpenter, Dean and Professor of Law .
  • As part of the Hybrid JD program, students learn from a premier faculty that includes patent experts, sports law leaders, technology law gurus, trademark scholars, and more.
  • Students will also benefit from the school's bar preparation program beginning in their 1L year and its Career Services Office which has dedicated career counselors for students in the hybrid JD program.

Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting

Retrieved on: 
Wednesday, September 13, 2023
DARPin, Partnership, AACR, Therapy, EANM, Half-life, RDT, Nuclear medicine, Delta, Radiation, DLL3, European Association of Nuclear Medicine, Novartis, Molecular Partners, Engineering, Kidney, Neoplasm, Radio, Pharmaceutical industry, Vaccine, CONCORD

These data will be presented at the European Association of Nuclear Medicine (EANM) Annual Meeting, held September 9–13 in Vienna, Austria and can be accessed here .

Key Points: 
  • These data will be presented at the European Association of Nuclear Medicine (EANM) Annual Meeting, held September 9–13 in Vienna, Austria and can be accessed here .
  • The data show the ability of Molecular Partners to substantially increase tumor uptake of RDT candidates through an adjustment of systemic half-life, achieved by binding to the common blood protein serum albumin.
  • With today’s data we show that tuning of half-life can substantially impact the tumor uptake of our Radio DARPins,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.

VLogic Systems, Inc. Appoints Terry R. Holmes as Chief Revenue Officer

Retrieved on: 
Thursday, August 31, 2023
Integrated workplace management system, University, Marketing, VM Software (company), Business, Fintech, Government, Facility management, Organization, Senior management, Growth, GTM, IWMS, Ross School of Business, Management, Health care, Energy, CONCORD

CONCORD, Mass., Aug. 31, 2023 /PRNewswire-PRWeb/ -- VLogic Systems, Inc. of Concord, Massachusetts, USA has announced that Terry R. Holmes has joined its Management Team as Chief Revenue Officer reporting to George Koshy, VLogic Systems CEO. Terry will be participating in the development of VLogic's GTM strategy and leading the sales and marketing execution of this strategy.

Key Points: 
  • VLogic Systems, Inc. based in Concord, Massachusetts USA has announced that Terry R. Holmes has joined VLogic Systems as Chief Revenue Officer.
  • CONCORD, Mass., Aug. 31, 2023 /PRNewswire-PRWeb/ -- VLogic Systems, Inc. of Concord, Massachusetts, USA has announced that Terry R. Holmes has joined its Management Team as Chief Revenue Officer reporting to George Koshy, VLogic Systems CEO.
  • "I am delighted to be joining VLogic Systems with their significant experience and leadership position in the rapidly growing Facilities Management IWMS software space," says Mr. Holmes.
  • When he is not engaged in VLogic Systems activities, Terry is active in his community and a pickleball enthusiast.